Screener
Integra LifeSciences IART Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Income tax payable | 3,236 | 3,651 |
| Accrued compensation | 68,177 | 74,079 |
| Accrued expenses and other current liabilities | 107,618 | 130,493 |
| Total current liabilities | 330,881 | 455,981 |
| Long-term borrowings under senior credit facility | 1,736,105 | 1,729,556 |
| Long-term borrowings under securitization facility | 92,600 | — |
| Lease liability - operating leases | 162,660 | 163,059 |
| Deferred tax liabilities | 3,470 | 5,664 |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's total current liabilities?
- Integra LifeSciences (IART) reported total current liabilities of $330.88M in Q2 2026.
- How has Integra LifeSciences's total current liabilities changed year-over-year?
- Integra LifeSciences's total current liabilities decreased by 64.4% year-over-year, from $929.81M to $330.88M.
- What is the long-term trend for Integra LifeSciences's total current liabilities?
- Over 5 years (2020 to 2025), Integra LifeSciences's total current liabilities has grown at a 2.6% compound annual growth rate (CAGR), from $401.01M to $455.98M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Integra LifeSciences's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude